Related Experiment Video
Updated: May 22, 2026

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
Published on: May 15, 2019
[Effects of triptolide on bortezomib-induced apoptosis in multiple myeloma cells]
Yang Yang1, Hong-Juan Dong, Guang-Xun Gao
1Department of Geriatric Hematology, Chinese PLA General Hospital, Beijing, China.
Abstract:
This study was purposed to investigate the effect of triptolide on bortezomib-induced apoptosis in multiple myeloma cell line NCI-H929(H929). MTT assay was applied to detect the inhibitory effects of triptolide and bortezomib alone or combined at different concentrations on H929 cells, the cell apoptosis was assayed by flow cytometry with Annexin V-FITC/PI staining. The results showed that both triptolide (10 - 100 ng/ml) and bortezomib (10 - 100 nmol/L) alone or combination inhibited the proliferation of MM cell line H929 in a concentration-dependent manner. The apoptotic rate of H929 cells in group of triptolide combined with bortezomib was much higher than that in groups of single drug or control; moreover, the apoptotic rate of H929 cells treated by non-inhibitory concentration of triptolide (10 ng/ml) combined with bortezomib (40 nmol/L) for 24 h was significantly higher than that by bortezomib alone (P < 0.05). It is concluded that triptolide can significantly enhance the pro-apoptotic activity of bortezomib in MM cells.
Insights
Triptolide enhances bortezomib-induced apoptosis in multiple myeloma cells. This combination therapy shows increased efficacy compared to single agents, offering a promising strategy for treating multiple myeloma.
Area of Science:
- Pharmacology
- Cancer Biology
- Cell Death Research
Context:
- Multiple myeloma (MM) is a hematologic malignancy.
- Bortezomib is a proteasome inhibitor used in MM treatment.
- Drug resistance remains a challenge in MM therapy.
Purpose:
- To investigate the synergistic effect of triptolide and bortezomib on multiple myeloma cells.
- To evaluate the impact of triptolide on bortezomib-induced apoptosis in NCI-H929 cells.
Summary:
- Triptolide and bortezomib inhibited proliferation of NCI-H929 cells in a dose-dependent manner.
- Combination treatment significantly increased the apoptotic rate compared to single-drug treatments.
- Even at a non-inhibitory concentration, triptolide potentiated bortezomib's apoptotic effect.
Impact:
- Triptolide can enhance the pro-apoptotic activity of bortezomib in multiple myeloma.
- This finding suggests a potential therapeutic strategy to improve bortezomib efficacy.
- Further research may explore triptolide as an adjunct therapy for multiple myeloma.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
The Intrinsic Apoptotic Pathway
Drugs that Stabilize Microtubules

